Capsugel Announces Expansion at Quakertown Facility
PTSM: Pharmaceutical Technology Sourcing and Management
Capsugel is expanding the facility to meet demand for micronization services for clinical and commercial manufacturing.
On Sept. 7, 2016, Capsugel announced that it will be expanding its Quakertown, PA facility to meet demand for micronization services for clinical and commercial manufacturing. The expansion will double the size of its current pilot-scale capacity for clinical-trial quantities and increase the number of suites for commercial manufacturing.
The Quakertown facility, which Capsugel acquired as part of its purchase of Xcelience and Powdersize in January 2016, operates as a full-service provider of particle-size reduction and particle-size control/classification technologies for pharmaceutical customers. The acquisition expanded the company’s suite of bioavailability tools aimed at improving the bioavailability of APIs with either dissolution or solubility challenges. In addition to enabling increased capacity, the added suites will include single-use containment technologies to accommodate potent and highly potent compounds. The new equipment and suites are scheduled to be operational by January 2017.
Source: Capsugel
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
